A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer

ConclusionsGVAX/Cy plus pembrolizumab failed to meet its primary objective in MMRp CRC. Biochemical responses were observed in a subset of patients and have not previously been observed with pembrolizumab monotherapy in MMRp CRC, indicating that GVAX may modulate the antitumor immune response.

Source: Cancer Medicine - December 25, 2019 Category: Cancer & Oncology Authors: Mark Yarchoan, Chiung ‐Yu Huang, Qingfeng Zhu, Anna K. Ferguson, Jennifer N. Durham, Robert A. Anders, Elizabeth D. Thompson, Noah S. Rozich, Dwayne L. Thomas, Julie M. Nauroth, Christina Rodriguez, Arsen Osipov, Ana De Jesus‐Acosta, Dung Tags: ORIGINAL RESEARCH Source Type: research